These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 21544715)
41. Novel antiplatelet drugs in clinical development. Ungerer M; Münch G Thromb Haemost; 2013 Nov; 110(5):868-75. PubMed ID: 24108565 [TBL] [Abstract][Full Text] [Related]
42. Antiplatelet therapy for atherothrombotic disease: how can we improve the outcomes? Moser M; Bode C J Thromb Thrombolysis; 2010 Aug; 30(2):240-9. PubMed ID: 20467788 [TBL] [Abstract][Full Text] [Related]
43. Discovery of nor-seco himbacine analogs as thrombin receptor antagonists. Chelliah MV; Chackalamannil S; Xia Y; Eagen K; Greenlee WJ; Ahn HS; Agans-Fantuzzi J; Boykow G; Hsieh Y; Bryant M; Chan TM; Chintala M Bioorg Med Chem Lett; 2012 Apr; 22(7):2544-9. PubMed ID: 22405832 [TBL] [Abstract][Full Text] [Related]
44. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157 [TBL] [Abstract][Full Text] [Related]
45. Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice? Menown IB Biomark Med; 2011 Feb; 5(1):1-3. PubMed ID: 21319960 [No Abstract] [Full Text] [Related]
46. M-AAA-thrombin: potent anticoagulant and antiplatelet thrombin derivative with differential affinity for factor VIII and PAR1. Hosokawa K; Matsuda H; Ohnishi T; Gonda M; Koide T Thromb Res; 2010 Nov; 126(5):447-53. PubMed ID: 20870278 [TBL] [Abstract][Full Text] [Related]
47. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. Chackalamannil S; Xia Y; Greenlee WJ; Clasby M; Doller D; Tsai H; Asberom T; Czarniecki M; Ahn HS; Boykow G; Foster C; Agans-Fantuzzi J; Bryant M; Lau J; Chintala M J Med Chem; 2005 Sep; 48(19):5884-7. PubMed ID: 16161991 [TBL] [Abstract][Full Text] [Related]
49. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Smith SM; Judge HM; Peters G; Armstrong M; Dupont A; Gaussem P; Storey RF Platelets; 2005 Sep; 16(6):340-5. PubMed ID: 16194864 [TBL] [Abstract][Full Text] [Related]
50. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Wu CC; Teng CM Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935 [TBL] [Abstract][Full Text] [Related]
51. G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents. Chackalamannil S Curr Top Med Chem; 2003; 3(10):1115-23. PubMed ID: 12769712 [TBL] [Abstract][Full Text] [Related]
52. Novel Antiplatelet Agents in Cardiovascular Disease. Tscharre M; Michelson AD; Gremmel T J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728 [TBL] [Abstract][Full Text] [Related]
53. [Place of ticlopidine in antiplatelet treatment]. Wlazłowski R; Goch A; Goch JH Pol Merkur Lekarski; 2005 Aug; 19(110):131-5. PubMed ID: 16245416 [TBL] [Abstract][Full Text] [Related]
55. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. ; Anand S; Yusuf S; Xie C; Pogue J; Eikelboom J; Budaj A; Sussex B; Liu L; Guzman R; Cina C; Crowell R; Keltai M; Gosselin G N Engl J Med; 2007 Jul; 357(3):217-27. PubMed ID: 17634457 [TBL] [Abstract][Full Text] [Related]
56. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Serebruany VL; Miller M; Pokov AN; Malinin AI; Lowry DR; Tanguay JF; Hennekens CH Am J Cardiol; 2006 May; 97(9):1332-6. PubMed ID: 16635606 [TBL] [Abstract][Full Text] [Related]
57. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1. Tsopanoglou NE; Maragoudakis ME Semin Thromb Hemost; 2007 Oct; 33(7):680-7. PubMed ID: 18000795 [TBL] [Abstract][Full Text] [Related]
58. Strategies for antiplatelet targets and agents. Xiang YZ; Kang LY; Gao XM; Shang HC; Zhang JH; Zhang BL Thromb Res; 2008; 123(1):35-49. PubMed ID: 18571699 [TBL] [Abstract][Full Text] [Related]
59. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Capodanno D; Dharmashankar K; Angiolillo DJ Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):151-8. PubMed ID: 20136601 [TBL] [Abstract][Full Text] [Related]
60. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. Chackalamannil S J Med Chem; 2006 Sep; 49(18):5389-403. PubMed ID: 16942011 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]